ESTRO Multidisciplinary Management of Breast Cancer 2017

Less local treatment: The role of RT in BCT

RT after tumorectomy: not always required?

Who decides?

Low risk:  the same in NL, UK, B, It, D, …?

• Countries with 5 y endocrine therapy for ALL ER+

•  Countries with endocrine therapy starting at intermediate

risk (≥ 5% recurrence or survival benefit)

• Side effects:

•

Very (too?) well documented and known for RT

•

Emerging knowledge for systemic therapy…